MAINZ

Mainz Biomed Reports Full Year 2023 Financial Results

Retrieved on: 
Tuesday, April 9, 2024
Gene expression, Colorectal cancer, Partnership, Patient, Biomarker, Gold, Pivotal, Messenger, Oncology, Science, PMA, CRC, EOL, Marketing, FDA, Physician, Quest Diagnostics, Vaccine

BERKELEY, Calif. and MAINZ, Germany, April 09, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today financial results for the fiscal year ended December 31, 2023.

Key Points: 
  • BERKELEY, Calif. and MAINZ, Germany, April 09, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today financial results for the fiscal year ended December 31, 2023.
  • “This past fiscal year represented an important period of progress for the Company highlighted by reporting results from our groundbreaking ColoFuture and eAArly DETECT studies which demonstrated extraordinary statistical significance for colorectal cancer (CRC) detection and advanced adenomas, a type of pre-cancerous polyp which are considered precursors to colorectal cancer,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed.
  • Final preparations for Pivotal FDA PMA clinical trial (ReconAAsense) evaluating gold standard self-administered CRC test - on track to commence patient enrollment in 2024.
  • Established commercial operations in major markets including Spain, Poland, Romania, Portugal, Israel, and the UK.

Three-year Phase 1 Follow-Up Data for mRNA-based Individualized Immunotherapy Candidate Show Persistence of Immune Response and Delayed Tumor Recurrence in Some Patients with Resected Pancreatic Cancer

Retrieved on: 
Sunday, April 7, 2024
BNTX, Survival, Entrepreneurship, Genentech, Disease, BioNTech, Patient, Neoplasm, Tissue, Messenger, PDAC, Roche, Uridine, Safety, Cancer, De novo, Recurrence, Blood, Vaccine

The data show that in 8 out of 16 patients autogene cevumeran elicited an immune response up to three years post administration measured by activated T cells.

Key Points: 
  • The data show that in 8 out of 16 patients autogene cevumeran elicited an immune response up to three years post administration measured by activated T cells.
  • The persistence of T cels was associated with a longer median recurrence-free survival in cancer vaccine responders.
  • “These new data are an early signal for the potential of our individualized mRNA cancer vaccine approach in this indication with an unmet medical need.
  • Over 80% of the vaccine-induced neoantigen-specific T cells could still be detected up to three years post administration in patients with an immune response.

BioNTech Announces Fourth Quarter and Full Year 2023 Financial Results and Corporate Update

Retrieved on: 
Wednesday, March 20, 2024

MAINZ, Germany, March 20, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) today reported financial results for the three months and full year ended December 31, 2023, and provided an update on its corporate progress.

Key Points: 
  • In 2023, BioNTech and Pfizer delivered more than 400 million COVID-19 vaccine doses worldwide.
  • To augment anti-tumor activity and to counteract resistance mechanisms, BioNTech seeks to combine compounds with non-overlapping, synergistic mechanisms of action.
  • S&P Global Ratings has rated BioNTech in the S&P Corporate Sustainability Assessment 2023 ("CSA") with an S&P Global CSA score of 45 (2022: 32) out of 100.
  • ET (1:00 p.m. CET) to report its financial results and provide a corporate update for the fourth quarter and financial year 2023.

BioNTech Announces Appointment of Annemarie Hanekamp to Management Board as Chief Commercial Officer

Retrieved on: 
Wednesday, March 20, 2024
Novartis, BNTX, Prostate cancer, Supervisory board, Survival, Science, BioNTech, COVID-19, Patient, Lung, Breast, Prostate, Cancer, Translation, Marketing, Development, Pharmaceutical industry

Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024.

Key Points: 
  • Mainz, Germany, March 20, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Annemarie Hanekamp to the Management Board as Chief Commercial Officer effective July 1, 2024.
  • Annemarie Hanekamp is a seasoned pharmaceutical executive experienced in developing patient-focused commercial strategies for innovative oncology products encompassing sales, marketing and market access.
  • I believe its COVID-19 vaccine will only be the beginning of a series of approved products to follow in the years to come,” said Annemarie Hanekamp, designated Chief Commercial Officer at BioNTech.
  • Annemarie Hanekamp is a Dutch citizen and holds degrees in biomedical sciences as well as organizational leadership.

Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment

Retrieved on: 
Tuesday, March 19, 2024
Diagnosis, Disease, Colorectal cancer, Incidence, Research, Cancer, Get Together, Recurrence, Medical device

BERKELEY, Calif. and MAINZ, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, will be organizing the HALLO DOC!

Key Points: 
  • BERKELEY, Calif. and MAINZ, Germany, March 19, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, will be organizing the HALLO DOC!
  • event, informing about colorectal cancer, cutting-edge research, new treatment modalities, and holistic therapeutic approaches.
  • This event will take place on March 20, 2024, in Berlin, Germany, aligning with the Colorectal Cancer Awareness Month.
  • Mainz Biomed has organized this event to shed light on new diagnostic methods, the importance of a comprehensive treatment approach, and the latest advancements in colorectal cancer research.

Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options

Retrieved on: 
Monday, March 18, 2024
Colorectal cancer, Large intestine, Marker beacon, Certification, Risk assessment, Pharmacist, Physician, BDH

BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.

Key Points: 
  • BERKELEY, Calif. and MAINZ, Germany, March 18, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, in collaboration with Ganzimmun, will host an educational webinar on Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options which is taking place on March 20, 2024.
  • Designed for pharmacists, physicians, and healthcare professionals, this online training session aims to shed light on innovative laboratory diagnostic approaches for colorectal cancer screening.
  • Set against the backdrop of March's Colorectal Cancer Awareness Month, the webinar will delve into the significance of genetic markers and the advancements in screening techniques that offer a more accurate risk assessment and early detection.
  • Title: Darmkrebs-Früherkennung: Neue labordiagnostische Optionen (Early Detection of Colorectal Cancer: New Laboratory Diagnostic Options)

Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

Retrieved on: 
Tuesday, March 12, 2024
Health, Union, Congress, DNA, Standard of care, Cancer, UDH, CRC, German, Pharmaceutical industry

Mainz Biomed’s showcase at the UDH Congress underscores the Company’s dedication to bridging the latest in scientific research with the wide spectrum of healthcare practices.

Key Points: 
  • Mainz Biomed’s showcase at the UDH Congress underscores the Company’s dedication to bridging the latest in scientific research with the wide spectrum of healthcare practices.
  • ColoAlert®, Mainz Biomed’s flagship product, is a testament to the Company’s mission, providing a highly accurate, easy-to-use, at-home colorectal cancer (CRC) screening kit.
  • By presenting ColoAlert® at the UDH Congress, Mainz Biomed highlights the role of cutting-edge molecular diagnostics in enhancing comprehensive health strategies, demonstrating the synergy between technological innovation and patient-centric care.
  • For more details on Mainz Biomed’s participation in the UDH Congress and to learn about the Company’s innovative diagnostic solutions, please visit Mainz Biomed’s official website at mainzbiomed.com.

BioNTech to Present Clinical Data Updates for Personalized mRNA-based and Targeted Oncology Candidates at AACR 2024

Retrieved on: 
Monday, March 11, 2024
NSCLC, Docetaxel, Messenger, BioNTech, Spacecraft, AACR, Entrepreneurship, ADC, Safety, Roche, Pharmacokinetics, PDAC, BNTX, Abstract, Patient, Clinical trial, Pancreatic cancer, Cancer, Vaccine

MAINZ, Germany, March 11, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association for Cancer Research (“AACR”) Annual Meeting 2024 in San Diego, California, from April 5-10, 2024.

Key Points: 
  • MAINZ, Germany, March 11, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association for Cancer Research (“AACR”) Annual Meeting 2024 in San Diego, California, from April 5-10, 2024.
  • The oral and poster presentations will feature BioNTech’s investigational mRNA-based cancer vaccine and novel investigational antibody-drug conjugate (“ADC”) approaches.
  • BioNTech has established a diversified clinical oncology pipeline of more than 20 clinical programs along mRNA-based therapeutic cancer vaccines, targeted therapies comprising cell therapies and ADCs, and novel immunomodulators in unmet medical need solid tumor indications.
  • These candidates are currently being evaluated in more than 30 clinical studies, including nine programs in advanced Phase 2 trials and two candidates in pivotal Phase 3 trials.

BioNTech Announces Planned Retirement of Sean Marett

Retrieved on: 
Thursday, March 7, 2024
Pfizer, Supervisory board, BioNTech, Entrepreneurship, IPO, Commercial, COVID-19, BNTX, Companion, Science, Research, Film industry

Mainz, Germany, March 7, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Sean Marett, Chief Business and Commercial Officer, will retire as planned from the Management Board of BioNTech.

Key Points: 
  • Mainz, Germany, March 7, 2024 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that Sean Marett, Chief Business and Commercial Officer, will retire as planned from the Management Board of BioNTech.
  • Sean Marett’s responsibilities as Chief Business Officer are beeing gradually transferred to James Ryan, Ph.D., Chief Legal Officer, who will also take on the role of Chief Business Officer of BioNTech at the end of the transition phase and upon Sean Marett’s retirement.
  • Sean Marett joined BioNTech as a member of the Management Board in 2012.
  • Sean Marett was a key member of the team that ensured liquidity of over $1 billion in funding as a private company.

BioNTech to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 20, 2024

Retrieved on: 
Wednesday, March 6, 2024
PIN, Webcast, BNTX, BioNTech, Telephone

MAINZ, Germany, March 6, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2023 on Wednesday, March 20, 2024.

Key Points: 
  • MAINZ, Germany, March 6, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the full year and fourth quarter 2023 on Wednesday, March 20, 2024.
  • Additionally, the Company will host a conference call and webcast that day at 8:00 a.m.
  • ET (2:00 p.m. CET) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update.
  • A replay of the webcast will be made available shortly after the call and archived on the Company’s website for 30 days following the call.